KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $17.1 million.

  • Royalty Pharma's Non Operating Income fell 7607.46% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.0 million, marking a year-over-year decrease of 23513.0%. This contributed to the annual value of $38.4 million for FY2024, which is 8154.79% down from last year.
  • As of Q3 2025, Royalty Pharma's Non Operating Income stood at $17.1 million, which was down 7607.46% from -$119.2 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Non Operating Income ranged from a high of $113.8 million in Q2 2022 and a low of -$127.4 million during Q4 2022
  • For the 5-year period, Royalty Pharma's Non Operating Income averaged around -$11.7 million, with its median value being -$27.2 million (2024).
  • As far as peak fluctuations go, Royalty Pharma's Non Operating Income tumbled by 28972.86% in 2021, and later surged by 34275.16% in 2024.
  • Royalty Pharma's Non Operating Income (Quarter) stood at -$99.7 million in 2021, then fell by 27.7% to -$127.4 million in 2022, then soared by 182.19% to $104.7 million in 2023, then plummeted by 125.95% to -$27.2 million in 2024, then skyrocketed by 162.79% to $17.1 million in 2025.
  • Its Non Operating Income stands at $17.1 million for Q3 2025, versus -$119.2 million for Q2 2025 and -$100.7 million for Q1 2025.